Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$20.0 million.

  • Indivior Pharmaceuticals' Cash from Investing Activities fell 15714.29% to -$20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.0 million, marking a year-over-year decrease of 14857.14%. This contributed to the annual value of $69.0 million for FY2024, which is 17263.16% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Cash from Investing Activities of -$20.0 million as of Q3 2025, which was down 15714.29% from -$17.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Cash from Investing Activities ranged from a high of $35.0 million in Q3 2024 and a low of -$127.0 million during Q1 2023
  • Moreover, its 4-year median value for Cash from Investing Activities was -$1.0 million (2022), whereas its average is -$9.8 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 360000.0% in 2024, then crashed by 180000.0% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Cash from Investing Activities stood at -$1.0 million in 2022, then surged by 1000.0% to $9.0 million in 2023, then decreased by 11.11% to $8.0 million in 2024, then plummeted by 350.0% to -$20.0 million in 2025.
  • Its Cash from Investing Activities was -$20.0 million in Q3 2025, compared to -$17.0 million in Q2 2025 and -$5.0 million in Q1 2025.